Dibakar Podder
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dibakar Podder has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Arijit Nag
6 shared publicationsMayur Parihar
6 shared publicationsReena Nair
6 shared publicationsRizwan Javed
6 shared publicationsSaswata Saha
6 shared publicationsShouriyo Ghosh
6 shared publications
Latest Publications
- Open Access
- 3 June 2026
- Published by Springer Nature in Cureus
- Vol. 18 (6)
Efficacy and Safety of Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia: A Single-Center Retrospective Analysis
Background Waldenström macroglobulinemia (WM) is a clonal B-cell lymphoproliferative disorder characterized by the presence of monoclonal IgM paraprotein. The traditional treatment approach was chemotherapy in combination with an anti-CD20 antibody. However, the treatment approach underwent a paradigm shift with the approval of Bruton tyrosine kinase inhibitors (BTKis). This retrospective analysis aims to highlight the efficacy and safety of BTKis in WM. Methodology Medical records of patients with WM who received BTKis were retrospectively reviewed. Relevant details regarding demographics, clinical and laboratory investigations, imaging reports, treatment, post-treatment response, adverse events, and infection were extracted from electronic medical records. Descriptive statistics and categorical variables were presented as frequencies and percentages. Survival outcomes were estimated by the Kaplan-Meier method. Results In total, 22 patients received BTKis. Of these, 12 patients received ibrutinib, whereas 10 patients received acalabrutinib. The median age was 64 years. MYD88 L265P positivity was seen in 19 (90.5%) cases, whereas CXCR4 mutations were seen in two (13.3%) cases. The most common indication for treatment with BTKis was anemia (n = 11, 50%). Overall response rate was seen in 18 (81.8%) cases, whereas major response rates were seen in 14 (63.7%) cases. At a median follow-up of 30 months, overall survival and progression-free survival were 91% (95% confidence interval (CI) = 0.87-0.95) and 82% (95% CI = 0.77-0.87), respectively. Neutropenia and thrombocytopenia were seen in 6 (27.3%) and 7 (31.8%) cases, respectively. Bleeding, arrhythmias, and infections were seen in 2 (9.1%), 3 (13.6%), and 18 (81.8%) cases, respectively. Conclusions BTKis are effective in WM but are associated with high rates of hematologic and non-hematologic side effects.
- 3 June 2026
- Published by Springer Nature in Cureus
- Vol. 18 (6)
Open AccessEfficacy and Safety of Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia: A Single-Center Retrospective Analysis
Background Waldenström macroglobulinemia (WM) is a clonal B-cell lymphoproliferative disorder characterized by the presence of monoclonal IgM paraprotein. The traditional treatment approach was chemotherapy in combination with an anti-CD20 antibody. However, the treatment approach underwent a paradigm shift with the approval of Bruton tyrosine kinase inhibitors (BTKis). This retrospective analysis aims to highlight the efficacy and safety of BTKis in WM. Methodology Medical records of patients with WM who received BTKis were retrospectively reviewed. Relevant details regarding demographics, clinical and laboratory investigations, imaging reports, treatment, post-treatment response, adverse events, and infection were extracted from electronic medical records. Descriptive statistics and categorical variables were presented as frequencies and percentages. Survival outcomes were estimated by the Kaplan-Meier method. Results In total, 22 patients received BTKis. Of these, 12 patients received ibrutinib, whereas 10 patients received acalabrutinib. The median age was 64 years. MYD88 L265P positivity was seen in 19 (90.5%) cases, whereas CXCR4 mutations were seen in two (13.3%) cases. The most common indication for treatment with BTKis was anemia (n = 11, 50%). Overall response rate was seen in 18 (81.8%) cases, whereas major response rates were seen in 14 (63.7%) cases. At a median follow-up of 30 months, overall survival and progression-free survival were 91% (95% confidence interval (CI) = 0.87-0.95) and 82% (95% CI = 0.77-0.87), respectively. Neutropenia and thrombocytopenia were seen in 6 (27.3%) and 7 (31.8%) cases, respectively. Bleeding, arrhythmias, and infections were seen in 2 (9.1%), 3 (13.6%), and 18 (81.8%) cases, respectively. Conclusions BTKis are effective in WM but are associated with high rates of hematologic and non-hematologic side effects.
- Open Access
Real world data on Solitary Plasmacytoma from eastern India- highlighting favorable trends in outcome
Introduction: Solitary plasmacytomas (SP) are rare neoplasm of localised proliferation of clonal plasma cells. It can be classified based on site of involvement and bone marrow involvement. It is an indolent disease in the majority of patients. Primary modality of treatment is radiotherapy and surgical excision. Materials and methods: This was a retrospective audit of SP who were treated and followed up at a tertiary care center in eastern India from January 2012 to December 2025. Patients who has solitary plasma cytoma with more than 10% plasma cells, POEMS syndrome, have been excluded from analysis. Results: We identified 46 patients of SP. The median age of the studied population was 53 years (23-75 years). Males were more commonly affected than females (M:F=2.2:1). Most common chief complaints were bony pain (67.4%). SBP was seen in 39 (84.8%) cases whereas SEP was seen in 7 (15.2%) cases. Vertebra was the most common site of involvement (61.4%). Median M band concentration 0.24 g/dL (0.1 to 1.95 gm/dL). IgG was the most common isotype accounting for 60.6% cases. Six cases (13%) had minimal bone marrow involvement. The majority of the patients received local radiotherapy (89.1%). With a median follow up of 5.4 years (95% CI: 1.8 – 9.0), median OS was not reached, median PFS was 9.22 years (95% CI: 5.8-12.6), median time to next treatment (TTNT) was 9.86 years (95% CI: 6.8 – 12.9). Conclusion: Solitary plasmacytoma commonly affects young males. Bones are more commonly affected than extramedullary sites. SP has a lower rate of progression and excellent prognosis when treated with local radiotherapy.
Open AccessReal world data on Solitary Plasmacytoma from eastern India- highlighting favorable trends in outcome
Introduction: Solitary plasmacytomas (SP) are rare neoplasm of localised proliferation of clonal plasma cells. It can be classified based on site of involvement and bone marrow involvement. It is an indolent disease in the majority of patients. Primary modality of treatment is radiotherapy and surgical excision. Materials and methods: This was a retrospective audit of SP who were treated and followed up at a tertiary care center in eastern India from January 2012 to December 2025. Patients who has solitary plasma cytoma with more than 10% plasma cells, POEMS syndrome, have been excluded from analysis. Results: We identified 46 patients of SP. The median age of the studied population was 53 years (23-75 years). Males were more commonly affected than females (M:F=2.2:1). Most common chief complaints were bony pain (67.4%). SBP was seen in 39 (84.8%) cases whereas SEP was seen in 7 (15.2%) cases. Vertebra was the most common site of involvement (61.4%). Median M band concentration 0.24 g/dL (0.1 to 1.95 gm/dL). IgG was the most common isotype accounting for 60.6% cases. Six cases (13%) had minimal bone marrow involvement. The majority of the patients received local radiotherapy (89.1%). With a median follow up of 5.4 years (95% CI: 1.8 – 9.0), median OS was not reached, median PFS was 9.22 years (95% CI: 5.8-12.6), median time to next treatment (TTNT) was 9.86 years (95% CI: 6.8 – 12.9). Conclusion: Solitary plasmacytoma commonly affects young males. Bones are more commonly affected than extramedullary sites. SP has a lower rate of progression and excellent prognosis when treated with local radiotherapy.
- Open Access
Clinico-pathologic characteristics, patterns of treatment and outcome of newly diagnosed Waldenstroms Macroglobulinemia- a single center real world retrospective analysis
Waldenstrom macroglobulinemia (WM) is a rare indolent neoplasm characterized by presence of more than 10% lymphoid cells in BM that exhibit plasmacytoid or plasma cell differentiation that secretes an IgM monoclonal protein. This is a retrospective analysis of 89 patients of WM that describes the clinical and laboratory characteristics, treatment patterns and outcome of patients of WM. The median age of the entire cophort was 66 years with male predominance (67.4%). Most common presentations were symptoms pertaining to anemia (77.5%) and constitutional symptoms (33.7%). Median bone marrow lymphoplasmacytic cells were 41%. Positivity for MYD88 and CXCR4 mutations were seen in 81.8% and 2.4% cases. BR was the most common regimen used (52.8%). Overall response rates were seen at 87.8%. Median overall survival, progression free survival and time to next treatment is 8.49 years, 2.15 years and 3.88 years. BR regimen was associated with highest event free survival.
Open AccessClinico-pathologic characteristics, patterns of treatment and outcome of newly diagnosed Waldenstroms Macroglobulinemia- a single center real world retrospective analysis
Waldenstrom macroglobulinemia (WM) is a rare indolent neoplasm characterized by presence of more than 10% lymphoid cells in BM that exhibit plasmacytoid or plasma cell differentiation that secretes an IgM monoclonal protein. This is a retrospective analysis of 89 patients of WM that describes the clinical and laboratory characteristics, treatment patterns and outcome of patients of WM. The median age of the entire cophort was 66 years with male predominance (67.4%). Most common presentations were symptoms pertaining to anemia (77.5%) and constitutional symptoms (33.7%). Median bone marrow lymphoplasmacytic cells were 41%. Positivity for MYD88 and CXCR4 mutations were seen in 81.8% and 2.4% cases. BR was the most common regimen used (52.8%). Overall response rates were seen at 87.8%. Median overall survival, progression free survival and time to next treatment is 8.49 years, 2.15 years and 3.88 years. BR regimen was associated with highest event free survival.
- 28 February 2026
- Published by Elsevier in Current Problems in Cancer
- Vol. 62, 101283
End-of-induction MRD predicts early survival in high-risk adult B-acute lymphoblastic leukemia: A study from Eastern India
- 28 February 2026
- Published by Elsevier in Current Problems in Cancer
- Vol. 62, 101283
End-of-induction MRD predicts early survival in high-risk adult B-acute lymphoblastic leukemia: A study from Eastern India
- 22 October 2025
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (5) , 1-7
Ponatinib in Chronic Myeloid Leukaemia Refractory To Multiple Tyrosine Kinase Inhibitors: Data from a Tertiary Care Centre in India
- 22 October 2025
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (5) , 1-7
Ponatinib in Chronic Myeloid Leukaemia Refractory To Multiple Tyrosine Kinase Inhibitors: Data from a Tertiary Care Centre in India